Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax

Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax

B cell prolymphocytic leukemia is a rare and aggressive disorder often with high risk features including TP53 mutation, deletion 17p and complex karyotype. There is scarcity of data regarding treatment and existing therapies induce short lived remissions. Ibrutinib, a Bruton tyrosine kinase inhibito...

Full description

Bibliographic Details
Main Authors: Maria Tariq Siddiqui, Allyson Price, Alessandra Ferrajoli, Gautam Borthakur
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Leukemia Research Reports
Subjects:
B cell prolymphocytic leukemia
Ibrutinib
Venetoclax
Deletion 17p
TP53
Online Access:http://www.sciencedirect.com/science/article/pii/S2213048921000339

Internet

http://www.sciencedirect.com/science/article/pii/S2213048921000339

Similar Items